“Bringing microarray scanning technology to clinical-quality standards is an important milestone in moving the advancement of genome-wide chromosome analysis to the clinic,” said Richard Choy, M.D., associate professor at the Chinese University of Hong Kong. “Agilent’s SureScan Dx scanner offers high resolution and sensitivity as well as dynamic autofocus to correct for differences in slide thickness. This means high-quality data for analysis.”
The product is CE marked for in-vitro diagnostic use in Europe and approved for the same use in South Korea and Singapore.
The SureScan Dx microarray scanner comes with an autoloader and Agilent Microarray Scan Control software. The system measures fluorescence signals from labeled DNA and RNA targets hybridized to microarrays, for example, to compare two DNA samples for differences, according to the company.
“We are pleased to introduce the SureScan Dx scanner in China for use in clinical laboratories," said Peter Serpentino, Agilent vice president and general manager for Genomics.
Agilent Technologies provides customers in more than 100 countries with laboratory instruments, services, consumables, applications and expertise. The Santa Clara, Calif.-based firm generated $4 billion in revenue in fiscal 2014. It employs about 12,000 people worldwide.